Leukemia Research
Volume 34, Issue 10 , Pages 1314-1319 , October 2010

Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia

  • Lei Cui

      Affiliations

    • Hematological Center, Beijing Children's Hospital Affiliated to Capital Medical University, 56 Nanlishi Road, Beijing 100045, China
    • ,
  • Zhigang Li

      Affiliations

    • Hematological Center, Beijing Children's Hospital Affiliated to Capital Medical University, 56 Nanlishi Road, Beijing 100045, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 010 68028401x2622; fax: +86 010 68055864.
    • ,
  • Minyuan Wu

      Affiliations

    • Hematological Center, Beijing Children's Hospital Affiliated to Capital Medical University, 56 Nanlishi Road, Beijing 100045, China
    • ,
  • Weijing Li

      Affiliations

    • Hematological Center, Beijing Children's Hospital Affiliated to Capital Medical University, 56 Nanlishi Road, Beijing 100045, China
    • ,
  • Chao Gao

      Affiliations

    • Hematological Center, Beijing Children's Hospital Affiliated to Capital Medical University, 56 Nanlishi Road, Beijing 100045, China
    • ,
  • Guoren Deng

      Affiliations

    • School of Medicine, University of California, San Francisco, CA, USA

Received 16 November 2009 ,Revised 16 November 2009 ,Accepted 30 November 2009.

References 

  1. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia – current status and future perspectives. Lancet Oncol. 2001;2:597–607
  2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–1043
  3. Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:2193–2194
  4. Gaynon PS, Trigg ME, Heerema NA, et al. Children's cancer group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia. 2000;14:2223–2233
  5. Izraeli S, Waldman D. Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges. Acta Haematol. 2004;112:34–39
  6. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771–782
  7. Ryan J, Quinn F, Meunier A, et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol. 2009;144:107–115
  8. Zhou J, Goldwasser MA, Li A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007;110:1607–1611
  9. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731–1738
  10. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550–554
  11. Nyvold C, Madsen HO, Ryder LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood. 2002;99:1253–1258
  12. Paganin M, Zecca M, Fabbri G, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia. Leukemia. 2008;22:2193–2200
  13. Donovan JW, Ladetto M, Zou G, et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood. 2000;95:2651–2658
  14. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52–58
  15. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691–2696
  16. Dworzak MN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99:1952–1958
  17. Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica. 2005;90:382–390
  18. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?. Leukemia. 2007;21:622–626
  19. Szczepanski T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002;15:37–57
  20. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–2317
  21. Verhagen OJ, Willemse MJ, Breunis WB, et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia. 2000;14:1426–1435
  22. Cui L, Li ZG, Gao C, Wu MY. Quantitative study of immunoglobulin heavy chain gene rearrangements in childhood acute lymphoblastic leukemia. Chin J Lab Med. 2007;30:1119–1122
  23. Chen X, Pan Q, Stow P, et al. Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay. Leukemia. 2001;15:166–170
  24. van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604–611
  25. Szczepanski T, Willemse MJ, van Wering ER, van Weerden JF, Kamps WA, van Dongen JJ. Precursor-B-ALL with D(H)–J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia. 2001;15:1415–1423
  26. Beishuizen A, Hahlen K, Hagemeijer A, et al. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia. 1991;5:657–667
  27. van Dongen JJ, Wolvers-Tettero IL. Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta. 1991;198:93–174
  28. Beishuizen A, Verhoeven MA, van Wering ER, Hahlen K, Hooijkaas H, van Dongen JJ. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood. 1994;83:2238–2247
  29. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013–1034
  30. Kitchingman GR. Immunoglobulin heavy chain gene VH-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia. Blood. 1993;81:775–782
  31. Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood. 2002;99:2315–2323
  32. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a children's oncology group study. Blood. 2008;111:5477–5485
  33. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591–598
  34. Brisco MJ, Sykes PJ, Dolman G, et al. Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia. Leukemia. 1997;11:1497–1500

PII: S0145-2126(09)00553-0

doi: 10.1016/j.leukres.2009.11.031

Leukemia Research
Volume 34, Issue 10 , Pages 1314-1319 , October 2010

Article Tools

* Image Usage & Resolution